###begin article-title 0
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily, contributes to acute and chronic disease processes, including sepsis.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 243 246 <span type="species:ncbi:10116">rat</span>
###xml 252 258 <span type="species:ncbi:10090">murine</span>
We studied the possible therapeutic role of RAGE inhibition in the cecal ligation and puncture (CLP) model of polymicrobial sepsis and a model of systemic listeriosis using mice genetically deficient in RAGE expression or mice injected with a rat anti-murine RAGE monoclonal antibody.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 52 56 52 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 62 64 62 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 71 73 71 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 111 115 111 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 121 123 121 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 293 295 293 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 611 614 611 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 620 623 620 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 697 720 697 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes </italic>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 697 719 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 778 782 <span type="species:ncbi:10090">mice</span>
The 7-day survival rates after CLP were 80% for RAGE-/- mice (n = 15) (P < 0.01 versus wild-type), 69% for RAGE+/- mice (n = 23), and 37% for wild-type mice (n = 27). Survival benefits were evident in BALB/c mice given anti-RAGE antibody (n = 15 per group) over serum-treated control animals (P < 0.05). Moreover, delayed treatment with anti-RAGE antibody up to 24 hours after CLP resulted in a significant survival benefit compared with control mice. There was no significant increase in tissue colony counts from enteric Gram-negative or Gram-positive bacteria in animals treated with anti-RAGE antibody. RAGE-/-, RAGE+/-, and anti-RAGE antibody-treated animals were resistant to lethality from Listeria monocytogenes by almost two orders of magnitude compared with wild-type mice.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Further studies are warranted to determine the clinical utility of anti-RAGE antibody as a novel treatment for sepsis.
###end p 9
###begin p 10
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
See related commentary by Clynes et al.,
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 990 991 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Sepsis is a major clinical problem in acute care medicine and surgery, and treatment options remain limited [1,2]. This unmet medical need has inspired a great deal of work to understand the molecular pathogenesis of sepsis and to develop improved therapeutic interventions. One molecule that has been implicated in the pathogenesis of sepsis is the receptor for advanced glycation end products (RAGE), a member of the immunoglobulin (Ig) superfamily [3,4]. It consists of an extracellular domain comprised of an Ig-like V-type domain and two Ig-like C-type domains, a single membrane-spanning domain, and a cytosolic tail [3]. The V-type domain and the cytoplasmic domain are important for ligand binding and for intracellular signaling, respectively. In addition to membrane-bound RAGE, soluble forms of RAGE (sRAGE) have been detected in plasma. Although the physiologic function of RAGE is unclear, it is involved in the inflammatory response and may have a role in neural development [5].
###end p 12
###begin p 13
###xml 259 261 259 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 587 612 587 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Porphyromonas gingivalis </italic>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 746 747 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 824 828 824 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 180 186 <span type="species:ncbi:9913">bovine</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 587 611 <span type="species:ncbi:837">Porphyromonas gingivalis</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
In several animals models, modulation of RAGE expression or activity has reduced inflammatory responses. In a model of delayed-type hypersensitivity, mice sensitized to methylated bovine serum albumin (mBSA) and administered sRAGE or anti-RAGE antibody (F(ab)2 fragment) had decreased inflammation following mBSA challenge [6]. In a study of chronic inflammation using an interleukin (IL)-10 null model of colitis, 6 weeks of treatment with sRAGE decreased the number of mice with colitis [6]. In streptozotocin-treated diabetic mice, sRAGE reduced periodontitis in mice challenged with Porphyromonas gingivalis [7]. Additionally, sRAGE reduced neutrophil extravasation into the peritoneum in thioglycollate-induced peritonitis in diabetic mice [8]. Reduced neutrophil migration into the peritoneum was also observed in RAGE-/- mice [9]. These studies suggest a role for RAGE in several disease settings.
###end p 13
###begin p 14
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 643 644 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 726 727 726 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
RAGE is expressed at low levels on multiple cell types. Expression is increased upon ligand interaction in chronic disease states such as rheumatoid arthritis [8,10] and diabetic nephropathy [11]. Ligands include advanced glycation end products (AGEs) which form in prolonged hyperglycemic states. However, AGEs may be only incidental, pathogenic ligands [6,12]. RAGE is a pattern-recognition receptor that binds diverse classes of endogenous molecules. Known ligands include high-mobility group box-1 (HMGB-1) [12], the S100/calgranulins [6], and peptides with a three-dimensional structure consisting of beta-sheet fibrils, such as amyloid [5,13]. RAGE is also a counter-receptor for the beta2-integrins Mac-1 and p150, 95 [9]. RAGE is part of a newly appreciated component of the innate immune system referred to as the damage-associated molecular pattern system [14,15].
###end p 14
###begin p 15
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 700 709 700 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 270 276 <span type="species:ncbi:10090">murine</span>
###xml 741 746 <span type="species:ncbi:9606">human</span>
HMGB-1 is an inflammatory cytokine and RAGE ligand that may be important in the septic response [6,12,16]. HMGB-1, also a DNA-binding protein, is released from cells due to necrosis or via a non-classical secretion pathway and is a late-stage mediator of lethality in a murine model of sepsis. Many of the RAGE ligands represent a unique class of molecules with both intra- and extracellular activities [14,15]. In a study using the cecal ligation and puncture (CLP) model of polymicrobial sepsis, HMGB-1 levels increased over the span of 1 to 2 days after CLP and remained elevated during the course of disease [17]. Mortality decreased in this model with administration of anti-HMGB-1 antibody. An in vitro study showed that activation of human umbilical venular endothelial cells by HMGB-1 was partially decreased by anti-RAGE antibodies given with the HMGB-1 [18]. The anti-RAGE antibodies did not affect stimulation with lipopolysaccharide or tumor necrosis factor (TNF)-alpha, implying that some elements of the inflammatory response induced by HMGB1 are mediated by RAGE.
###end p 15
###begin p 16
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 401 405 401 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 555 559 555 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
In a study by Liliensiek and colleagues [19], the genomic deletion of RAGE resulted in a decreased septic response, 80% of RAGE knockout mice survived the lethal effects of CLP, whereas only 20% of wild-type mice survived. Administration of sRAGE to block RAGE ligands also increased survival to 40% compared with 17% in the control group. There were fewer inflammatory cells on the peritoneum of RAGE-/- mice compared with wild-type mice after CLP; however, cytokine levels and inflammatory cells in the blood were similar between wild-type mice and RAGE-/- mice. The study suggests that RAGE may be a mediator in polymicrobial sepsis and that modulation may affect the pathophysiology.
###end p 16
###begin p 17
###xml 520 524 520 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 585 589 585 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 597 601 597 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 678 701 678 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes </italic>
###xml 162 165 <span type="species:ncbi:10116">rat</span>
###xml 171 177 <span type="species:ncbi:10090">murine</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 678 700 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
We hypothesized that treatment with an anti-RAGE antibody may have a protective effect in polymicrobial sepsis. Our experiments show that the administration of a rat anti-murine RAGE increased survival in the CLP model of sepsis compared with mice given control serum, even with delayed administration as long as 24 hours after CLP. Additionally, our studies confirm the finding that homozygous RAGE knockout mice survive polymicrobial sepsis at a higher rate compared with wild-type mice and show that heterozygous RAGE+/- mice have a similar survival rate. Finally, we show that RAGE-/- and RAGE+/- mice and RAGE monoclonal antibody (mAb)-treated mice also survive a systemic Listeria monocytogenes challenge significantly better than wild-type mice. These results demonstrate that RAGE may play an important role in the pathogenesis of sepsis in the CLP model and that anti-RAGE mAbs can increase the survival of septic mice.
###end p 17
###begin title 18
Materials and methods
###end title 18
###begin title 19
Materials and bacterial strains
###end title 19
###begin p 20
###xml 779 796 775 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 118 124 <span type="species:ncbi:10090">murine</span>
###xml 207 210 <span type="species:ncbi:10116">rat</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 282 288 <span type="species:ncbi:10090">murine</span>
###xml 779 795 <span type="species:ncbi:1639">L. monocytogenes</span>
Reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. The IgG2b anti-murine RAGE mAb was developed by Wyeth (Cambridge, MA, USA). This mAb is a high-affinity rat-derived anti-mouse RAGE antibody with a binding affinity of 0.3 nM for murine dimeric RAGE and binds to the N-terminal region of RAGE. Specificity of the antibody was demonstrated by binding to RAGE on the cell surface, direct binding to sRAGE, and immunohistochemistry (manuscript in preparation). Endotoxin levels were measured in all antibody preparations and were less than 1 endotoxin unit/mg protein. The high-affinity IgG hamster anti-TNF-alpha neutralizing mAb TN3.1912 was provided as a gift from Celltech LTD (Slough, Berkshire, UK). The challenge strain of L. monocytogenes was purchased from American Type Culture Collection (ATCC # 19115; Manassas, VA, USA).
###end p 20
###begin title 21
Animal strains and animal husbandry
###end title 21
###begin p 22
###xml 180 184 180 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 223 227 223 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 267 271 267 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 716 720 716 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 835 838 835 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 844 847 844 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 857 861 857 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 346 351 <span type="species:ncbi:10090">mouse</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 1199 1210 <span type="species:ncbi:3704">horseradish</span>
###xml 1238 1244 <span type="species:ncbi:9793">donkey</span>
###xml 1319 1323 <span type="species:ncbi:10090">mice</span>
###xml 1335 1339 <span type="species:ncbi:10090">mice</span>
Mouse strains used in these experiments were 2 to 6 months old and were specific-pathogen-free. BALB/c mice (Charles River Laboratories, Inc., Wilmington, MA, USA), homozygous RAGE-/- 129SvEvBrd male mice, heterozygous RAGE+/- 129SvEvBrd male mice, and wild-type RAGE+/+ 129SvEvBrd male mice (bred in-house at Wyeth) were used. The RAGE knockout mouse was designed at Wyeth Research (generated at Lexicon Genetics Incorporated, The Woodlands, TX, USA) as a gene targeted conditional knockout in 129SvEv-Brd mice in which Cre recombinase excises exons 2, 3, and 4. The resulting deletion results in a frame shift and truncation of the RAGE protein, and protein is not produced. The absence of RAGE protein in the RAGE-/- mice was confirmed by Western immunoblot analysis of lung tissue lysates. Lungs were harvested from individual RAGE+/+, RAGE+/-, and RAGE-/- animals and were flash-frozen. The tissue was lysed with radio-immunoprecipitation assay buffer. Equivalent amounts of total protein from each sample were analyzed by electrophoresis on a NuPAGE 4% to 12% Bis-Tris gel (Invitrogen Corporation, Carlsbad, CA, USA) and detected with immunodetection with the RAGE mAb or actin antibody and a horseradish peroxidase-conjugated anti-donkey antibody using standard protocols. RAGE is not essential for viability in mice; RAGE null mice have no obvious phenotype and breed normally.
###end p 22
###begin p 23
###xml 369 380 369 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum </italic>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
Animals were housed in an Institutional Animal Care and Use Committee (IUCAC)-approved facility under Biosafety Level 2 conditions and monitored by Brown University veterinary staff. Cages were covered with high-efficiency particulate air filters and maintained at constant ambient temperature and humidity with 12-hour day-night cycling. Animals were provided with an ad libitum supply of commercial mouse chow and distilled water and allowed to adjust to laboratory conditions for at least 7 days before undergoing experimental procedures. The experimental protocol was approved by the IUCAC before any procedures were undertaken.
###end p 23
###begin title 24
Cecal ligation and puncture model
###end title 24
###begin p 25
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The CLP procedure has been described previously [20]. Briefly, animals were anesthetized with an intraperitoneal injection of 200 muL of a combination of ketamine (Bedford Laboratories, Bedford, OH, USA) (9 mg/mL) and xylazine (Phoenix Pharmaceutical, Inc., St. Joseph, MO, USA) (1 mg/mL). The cecum was exteriorized through a midline abdominal incision of approximately 1 cm. The cecum was ligated with 5.0 monofilament just distal to the ileocecal junction (greater than 90% of the cecum ligated). The ante-mesenteric side of the cecum was punctured through and through with a 23-gauge needle. A scant amount of luminal content was expressed through both puncture sites to ensure patency. The cecum was returned to the abdominal cavity, and the fascia and skin incisions were closed with 6.0 monofilament and surgical staples, respectively. Topical 1% lidocaine and bacitracin were applied to the surgical site post-operatively. All animals received a single intramuscular injection of trovafloxacin (Pfizer Inc, New York, NY, USA) at a dose of 20 mg/kg and subcutaneous fluid resuscitation with 1.0 mL of normal saline immediately post-operatively. Animals were then returned to their individual cages and rewarmed using heat lamps until they regained normal posture and mobility.
###end p 25
###begin p 26
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">Mice</span>
Anti-RAGE mAb at 7.5 mg/kg or 15 mg/kg (or 1% autologous mouse serum control) was given once intravenously to wild-type 129SvEvBrd or BALB/c mice 30 to 60 minutes before CLP or at the following time intervals after CLP: 6, 12, 24, or 36 hours. Five animals underwent sham surgery (laparotomy with exteriorization of the cecum but without ligation or puncture). Mice were assessed for survival up to 7 days following surgery.
###end p 26
###begin title 27
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine listeriosis challenge model
###end title 27
###begin p 28
###xml 23 40 23 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 191 193 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 480 482 468 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 487 489 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 519 536 507 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 607 609 595 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 646 650 634 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 665 669 653 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 870 886 858 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 23 39 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 419 424 <span type="species:ncbi:9940">sheep</span>
###xml 519 535 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 870 886 <span type="species:ncbi:1639">L. monocytogenes</span>
A standard inoculum of L. monocytogenes was prepared from cultures grown 18 hours at 37degreesC in trypticase soy broth (TSB) (BBL, Cockeysville, MD, USA). Bacteria were centrifuged at 10,000g for 15 minutes at 4degreesC and resuspended in phosphate-buffered saline. Bacterial concentrations were adjusted spectrophotometrically and checked by quantitative dilutional plate counts on trypticase soy agar plates with 5% sheep red blood cells (BBL). Serial dilutions ranging from 103 to 106 colony-forming units (CFU) of L. monocytogenes were administered intravenously to determine the median lethal dose (LD50) for wild-type mice, homozygous RAGE-/- knockouts, RAGE+/- heterozygotes, and BALB/c mice given 15 mg/kg anti-RAGE mAb intravenously 1 hour before bacterial challenge. Animals were followed for 7 days after the administration of the intravenous challenge with L. monocytogenes. Survivors were euthanized for tissue analysis and microbiologic study.
###end p 28
###begin p 29
###xml 110 112 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 299 302 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 321 325 321 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 349 351 349 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 406 423 406 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 268 274 <span type="species:ncbi:10090">murine</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 406 422 <span type="species:ncbi:1639">L. monocytogenes</span>
For the detailed differential quantitative microbiology and cytokine determinations, a standard inoculum of 104 CFU was given intraperitoneally 1 hour after an intravenous infusion of anti-RAGE mAb (15 mg/kg), anti-TNF mAb (20 mg/kg), or equal volume of 1% autologous murine serum as a control. RAGE+/+, RAGE+/-, and RAGE-/- mice were also studied (n = 5 per group). Animals were euthanized 48 hours after L. monocytogenes challenge, and quantitative microbiology was performed from liver and spleen tissues by mincing the tissue samples with serial dilution on blood agar plates.
###end p 29
###begin p 30
###xml 73 75 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Injections and manipulations of the animals were conducted under light CO2 anesthesia to minimize stress to the experimental animals. Animals were monitored daily for survival. Moribund animals (hypothermia below 33degreesC and inactive with loss of righting response) were euthanized and scored as lethally infected animals.
###end p 30
###begin title 31
Tissue collection and cytokine measurement
###end title 31
###begin p 32
Quantitative microbiology was performed from organ samples obtained at necropsy in both the CLP and listeriosis experiments. Blood samples were obtained from surviving animals at the time of sacrifice, and serum was collected and immediately placed on ice for cytokine determination. Serum cytokines were measured by an enzyme-linked immunosorbent multiplex assay using the custom-made plates and protocol provided by Meso Scale Discovery (Gaithersburg, MD, USA). Cytokines assayed were monocyte chemoattractant protein-1 (MCP-1), IL-1-beta, TNF-alpha, interferon-gamma, and IL-6. Tissue samples were collected from the lung, liver, and spleen. Peritoneal fluid was obtained by lavaging the peritoneal cavity with 5 mL of sterile saline and withdrawing the fluid. Organ tissues were weighed and then pulverized to generate a suspension of tissue in TSB. Specimens were serially diluted and cultured at 37degreesC aerobically on TSB (for Gram-negative and Gram-positive bacteria) and MacConkey agar (for Gram-negative bacteria) to obtain quantitative bacterial counts standardized per gram of organ weight or CFU per milliliter of peritoneal lavage fluid.
###end p 32
###begin p 33
Tissues (lung, distal ileum) were analyzed by a pathologist blinded to the treatment assignment of each animal and scored on a defined pathology score graded from 0 (normal) to 4 (diffuse and extensive necrosis). Total lung water as a measure of pulmonary edema was calculated from wet-to-dry ratios of lung tissue.
###end p 33
###begin title 34
Statistical design and data analysis
###end title 34
###begin p 35
###xml 519 521 517 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 730 732 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The primary endpoint in each experiment was survival. Experiments were performed using a numeric code that blinded the investigators to the animal genotype or antibody treatment (versus serum control) until completion of the study. Numeric data are presented as mean (+/- standard error of the mean). Differences in survival were analyzed by a Kaplan-Meier survival plot and the log-rank statistic. The non-parametric one-way analysis of variance statistic Kruskal-Wallis test (for multiple groups) or the Mann-Whitney U test (for two groups) was used to analyze differences between groups. The Dunn multiple comparisons post-test was used to confirm differences when analyzing comparisons involving multiple groups. A two-tailed P value of less than 0.05 was considered significant.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Survival of homozygous RAGE knockouts, RAGE heterozygotes, and wild-type animals after cecal ligation and puncture
###end title 37
###begin p 38
###xml 27 29 27 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 59 61 59 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 169 173 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 182 184 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 191 193 191 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 334 338 334 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 349 352 349 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 354 356 354 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 416 418 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Homozygous RAGE knockouts (n = 15) and RAGE heterozygotes (n = 23) showed a significant degree of protection from the lethal effects of CLP compared with wild-type RAGE +/+ animals (n = 15) (P < 0.001) (Figure 1). RAGE heterozygotes were protected from lethal polymicrobial sepsis nearly as well as the homozygous RAGE knockouts (RAGE-/- versus RAGE+/-; P = not significant [ns]). As expected, sham surgery animals (n = 5) all survived. An additional group of 15 wild-type 129SvEvBrd animals were given anti-RAGE mAb 30 to 60 minutes before CLP and had a survival advantage similar to that of the RAGE knockouts when compared with the wild-type, serum-treated, control animals (Figure 1).
###end p 38
###begin p 39
###xml 204 208 204 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 225 227 225 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 238 242 238 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 248 250 248 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 261 265 261 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 271 273 271 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 391 393 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 525 527 525 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
Modulation of receptor for advanced glycation end products (RAGE) protects mice from the effects of cecal ligation and puncture (CLP). Kaplan-Meier survival analysis following CLP comparing wild-type RAGE+/+ 129SvEvBrd mice (n = 15), RAGE-/- mice (n = 15), RAGE+/- mice (n = 23), and anti-RAGE monoclonal antibody-treated (15 mg/kg intravenously 30 to 60 minutes before CLP) wild-type mice (n = 15). P < 0.001 for each group in comparison with the wild-type CLP control group. Sham surgery-treated wild-type 129SvEvBrd mice (n = 5) were used as an additional control group. WT, wild-type.
###end p 39
###begin p 40
###xml 191 195 191 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 292 296 292 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
The expression of RAGE protein was examined by Western immunoblot analysis of lung tissue where RAGE is constitutively expressed at high levels. In contrast to the expression of RAGE in RAGE +/+ mice, no RAGE protein was detected in the lungs of RAGE-/- mice. The levels of expression in RAGE+/- mice were reduced compared with wild-type mice (Figure 2).
###end p 40
###begin p 41
###xml 106 110 106 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 130 134 130 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 158 162 158 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
Receptor for advanced glycation end products (RAGE) protein expression in lung tissue from individual RAGE-/- (lanes 1 to 3), RAGE+/- (lanes 4 to 6), and RAGE+/+ (lanes 7 to 9) animals. Actin was used to demonstrate equal loading.
###end p 41
###begin p 42
###xml 600 604 598 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 627 631 623 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 661 663 655 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
Tissue colony counts for aerobic Gram-positive and Gram-negative enteric bacterial organisms following CLP were assessed to determine whether RAGE knockouts, RAGE heterozygotes, or anti-RAGE mAb-treated mice were different from wild-type mice or control-treated mice. No significant differences were found in liver and splenic tissues and peritoneal fluid, except that all were significantly higher than in sham-operated animals. The homozygous RAGE knockouts had the lowest amount of lung water compared with other groups, although this did not reach significance (wet-to-dry ratio: 4.8 +/- 0.2 RAGE-/- versus 5.0 +/- 0.4 RAGE+/- versus 5.3 +/- 0.3 wild-type; P = ns).
###end p 42
###begin title 43
Effects of anti-RAGE antibody with cecal ligation and puncture
###end title 43
###begin p 44
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 159 161 159 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 186 188 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 339 341 339 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 689 690 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 926 927 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
There was a significant difference in survival in BALB/c animals given control serum (n = 15) compared with animals given anti-RAGE antibody (7.5 mg/kg group [n = 15] or 15 mg/kg group [n = 15]) 30 to 60 minutes before CLP (Figure 3). Optimal protective effects were achieved at 15 mg/kg of anti-RAGE mAb (P < 0.05 versus 7.5 mg/kg group; P < 0.001 versus serum control), and this dose was employed in subsequent experiments with delayed mAb treatment. Animals given anti-RAGE antibody did not have significantly increased organ bacterial loads compared with control animals, but both groups had significantly more CFU/g of spleen and liver tissue than sham-treated control animals (Table 1). Histopathology of lung tissue and small bowel mucosa at necropsy was markedly abnormal in the serum control group, whereas pathological findings were significantly reduced in the anti-RAGE mAb group and the sham surgery group (Table 1).
###end p 44
###begin p 45
###xml 235 237 235 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 256 258 256 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 437 439 437 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 465 467 465 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Lethality from cecal ligation and puncture (CLP) is decreased in BALB/c mice administered an anti-RAGE monoclonal antibody (mAb). The Kaplan-Meier survival analysis following CLP compares anti-RAGE mAb-treated animals given 7.5 mg/kg (n = 15) or 15 mg/kg (n = 15) intravenously 30 to 60 minutes before CLP with serum control animals (n = 15). The group given 15 mg/kg had a significantly greater survival than the group given 7.5 mg/kg (P < 0.05) or serum control (P < 0.001). RAGE, receptor for advanced glycation end products.
###end p 45
###begin p 46
Microbiologic and pathologic findings following anti-RAGE mAb therapy in cecal ligation and puncture
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
aP < 0.05 sham versus other groups; bP < 0.005 control versus sham or anti-RAGE mAb. CFU, colony-forming units; mAb, monoclonal antibody; RAGE, receptor for advanced glycation end products.
###end p 47
###begin title 48
Survival of animals with delayed administration of anti-RAGE mAb after cecal ligation and puncture
###end title 48
###begin p 49
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 198 200 198 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 522 524 522 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The effects of delayed administration of a single 15 mg/kg dose of anti-RAGE antibody are shown in Figure 4. The administration of RAGE mAb provided significant protection up to 24 hours after CLP (P < 0.01). Delayed mAb administration 36 hours after CLP showed a favorable survival trend, but the differences were no longer significant compared with the serum-treated control group (P = 0.12). The tissue concentrations of aerobic enteric Gram-negative and Gram-positive bacteria did not differ between treatment groups (P = ns).
###end p 49
###begin p 50
###xml 362 364 362 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 421 423 421 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
Delayed administration of the anti-RAGE antibody is protective in cecal ligation and puncture (CLP). The Kaplan-Meier survival analysis following CLP in BALB/c mice compares delayed anti-RAGE monoclonal antibody (mAb) treatment given at various time intervals after CLP with serum control. Each group had a significantly greater survival than the control group (P < 0.01), except for the 36-hour delayed treatment group (P = 0.12). RAGE, receptor for advanced glycation end products.
###end p 50
###begin title 51
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes </italic>
###xml 0 22 <span type="species:ncbi:1639">Listeria monocytogenes</span>
Listeria monocytogenes challenge
###end title 51
###begin p 52
###xml 21 37 21 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes</italic>
###xml 45 48 45 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 124 128 120 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 167 171 161 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 203 207 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 271 274 263 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 331 333 323 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 547 550 539 542 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 568 570 558 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 711 715 701 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 765 769 755 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 778 780 768 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 21 37 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
When challenged with L. monocytogenes, the LD50 (log10) values were 3.30 +/- 0.12 for BALB/c mice, 3.31 +/- 0.2 CFU for RAGE+/+ 129SvEvBrd mice, 5.98 +/- 0.39 for RAGE+/- mice, and 5.10 +/- 0.47 for RAGE-/- mice. This difference of more than two orders of magnitude in LD50 from systemic listeriosis was statistically significant (P < 0.01) for both the RAGE heterozygotes and homozygotes compared with wild-type mice. A single dose of anti-RAGE antibody also provided BALB/c mice significant protection from lethal systemic listeriosis with an LD50 of 4.69 +/- 0.55 (P < 0.05 versus BALB/c control). The level of protection against listeriosis provided by the anti-RAGE mAb was similar to that observed in RAGE-/- animals but was not as great as that afforded RAGE+/- animals (P < 0.05).
###end p 52
###begin p 53
###xml 69 86 69 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 188 190 188 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 213 217 213 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 227 231 227 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 241 245 241 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 450 467 450 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 521 523 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 69 85 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 450 466 <span type="species:ncbi:1639">L. monocytogenes</span>
There was no statistically significant difference in the quantity of L. monocytogenes isolated in liver and spleen tissues following a standard systemic challenge of 104 CFU among groups (n = 10 per group) of RAGE+/+ mice, RAGE-/- mice, RAGE+/- mice, or BALB/c mice given anti-RAGE mAb (Figure 5). However, as expected, there was a highly statistically significant increase in organ bacterial concentrations in BALB/c mice given the same inoculum of L. monocytogenes following the administration of an anti-TNF antibody (P < 0.001).
###end p 53
###begin p 54
###xml 131 153 131 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes</italic>
###xml 178 195 178 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 231 233 231 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 339 341 339 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 131 153 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 178 194 <span type="species:ncbi:1639">L. monocytogenes</span>
Inhibition or deletion of receptor for advanced glycation end products (RAGE) does not disrupt the host mechanism for clearance of Listeria monocytogenes. Quantitative levels of L. monocytogenes in organ samples (liver and spleen, n = 10 per group) 48 hours after an intraperitoneal injection of 104 colony-forming units (CFU) per animal (P < 0.001 anti-tumor necrosis factor [TNF] monoclonal antibody [mAb] group versus all other groups).
###end p 54
###begin p 55
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria </italic>
###xml 111 115 107 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 138 142 134 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 155 156 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 538 540 522 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 631 633 611 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 763 767 <span type="species:ncbi:10090">mice</span>
Cytokine determinations after Listeria challenge showed a significantly lower level of interferon-gamma in RAGE-/- mice compared with RAGE+/+ mice (Figure 6). The BALB/c mice administered anti-TNF mAb had a significantly higher level of interferon-gamma compared with BALB/c controls, whereas the animals given anti-RAGE mAb had interferon-gamma levels that were not statistically different compared with control animals. Similar results were observed with IL-6 (anti-TNF mAb group 459 +/- 121 pg/mL versus control group 38 +/- 14 pg/mL; P < 0.01) and MCP-1 (anti-TNF mAb 1,363 +/- 480 pg/mL versus control group 566 +/- 70 pg/mL; P < 0.05). No significant differences were found in IL-6 or MCP-1 levels in RAGE-deficient animals or in anti-RAGE antibody-treated mice compared with the control group. Other cytokine determinations showed no significant differences.
###end p 55
###begin p 56
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 99 122 99 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes </italic>
###xml 133 135 133 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 157 159 157 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 243 247 243 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 99 121 <span type="species:ncbi:1639">Listeria monocytogenes</span>
Interferon-gamma levels following intraperitoneal challenge with 104 colony-forming units (CFU) of Listeria monocytogenes are shown (n = 10 for each group). P < 0.05 for anti-tumor necrosis factor (TNF) monoclonal antibody (mAb) group and RAGE-/- group, both versus control group. RAGE, receptor for advanced glycation end products.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 311 315 311 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 671 688 671 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 96 102 <span type="species:ncbi:10090">murine</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 671 687 <span type="species:ncbi:1639">L. monocytogenes</span>
These results support the beneficial effects of treatment with anti-RAGE antibody in a standard murine model of polymicrobial, intra-abdominal sepsis. We have confirmed that homozygous RAGE knockouts have increased survival compared with wild-type mice in the CLP model of sepsis. In addition, heterozygous RAGE+/- mice were similarly protected compared with wild-type mice. RAGE suppression did not increase tissue colony counts from enteric Gram-negative or Gram-positive bacteria. These results show that the modulation of RAGE protected mice from the lethal effects of CLP-induced sepsis. RAGE expression is highly detrimental to animals challenged systemically with L. monocytogenes as evidenced by the marked survival benefits observed in homozygous RAGE knockouts and heterozygotes compared with wild-type animals. The precise mechanism of these benefits is unclear and under investigation.
###end p 58
###begin p 59
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
The finding that homozygous and heterozygous RAGE knockout mice survive sepsis at higher rates than wild-type animals seems counterintuitive from an evolutionary standpoint. Speculation as to the reason for the persistence of a widely expressed and seemingly disadvantageous gene in the mammalian genome is hampered by the lack of a detailed understanding of RAGE's physiologic role. An intriguing finding is that, contrary to many systems designed to maintain homeostasis, RAGE expression is increased in inflammatory states when it binds to its ligands [21,22]. This positive feedback mechanism might function counter to homeostatic mechanisms in the presence of a massive inflammatory insult and hasten death of a severely ill animal.
###end p 59
###begin p 60
Given the finding of increased survival with polymicrobial sepsis in RAGE knockout animals, we hypothesized that treatment with an anti-RAGE antibody would increase survival. Our RAGE knockout animals, however, may have developed compensatory mechanisms that alter their inflammatory response. The experiment showing increased survival in animals administered the anti-RAGE antibody confirms that the benefit is present in situations in which physiologic compensation for genetic deficiency could not have occurred. This opens up an entirely new avenue for the treatment of severe sepsis and suggests that inhibition of the RAGE pathway may be an effective approach for treatment of sepsis in clinical settings.
###end p 60
###begin p 61
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Activation of the RAGE receptor triggers signaling cascades leading to sustained cellular activation, increase of RAGE itself, and propagation of the response. HMGB-1 and other RAGE ligands may contribute to damage and host response as part of the danger-associated molecular pattern system [14,15]. In animal models, HMGB-1 is a mediator of severe sepsis, and an anti-HMGB-1 antibody decreased mortality in the CLP model of sepsis [6,12,16]. In this study, the administration of anti-RAGE mAb and a genetic deletion of RAGE conferred resistance to the lethal effects of CLP. Additionally, delayed treatment with the anti-RAGE antibody up to 24 hours after CLP resulted in a significant survival benefit, suggesting that disruption of the interaction between RAGE and RAGE ligands is beneficial in this setting.
###end p 61
###begin p 62
###xml 9 26 9 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 304 313 304 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria </italic>
###xml 566 583 566 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 681 698 681 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L. monocytogenes </italic>
###xml 942 951 942 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria </italic>
###xml 1140 1149 1140 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria </italic>
###xml 9 25 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">Mice</span>
###xml 566 582 <span type="species:ncbi:1639">L. monocytogenes</span>
###xml 681 697 <span type="species:ncbi:1639">L. monocytogenes</span>
Systemic L. monocytogenes challenge is a classic model for study of the innate and acquired immune response in mice [23,24]. RAGE blockade or insufficiency due to administration of anti-RAGE antibody or as observed in RAGE null or RAGE heterozygous animals did not produce significant sensitivity to the Listeria challenge compared with wild-type animals, indicating that the deleterious effects of RAGE are present in an inflammatory state other than that accompanying polymicrobial sepsis. Mice administered anti-RAGE mAb and RAGE knockout animals appear to clear L. monocytogenes as well as wild-type animals. This is in contrast to animals given anti-TNF antibody in which the L. monocytogenes colony counts in tissue samples were markedly increased. Previous studies have demonstrated that anti-TNF antibodies suppress the innate immune response and increase the sensitivity to challenge. Similarly, cytokine levels were increased after Listeria challenge in animals given anti-TNF mAb. However, the levels were similar in animals given the anti-RAGE antibody and the control animals, consistent with no increase in sensitivity to the Listeria challenge.
###end p 62
###begin p 63
###xml 280 288 <span type="species:ncbi:9606">patients</span>
The finding of a survival benefit after delayed administration of anti-RAGE antibody was encouraging. This may have important clinical implications since an intervention such as anti-RAGE antibody treatment typically cannot be given immediately after the inciting event in septic patients.
###end p 63
###begin title 64
Conclusion
###end title 64
###begin p 65
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 344 350 <span type="species:ncbi:9606">humans</span>
These data provide support for the use of anti-RAGE mAb as a salvage therapy for patients with established severe sepsis. Inhibition of the RAGE pathway may be an effective approach for treatment of sepsis in clinical settings. Further pre-clinical and clinical investigations will be necessary to determine the feasibility of this strategy in humans with life-threatening sepsis or septic shock.
###end p 65
###begin title 66
Key messages
###end title 66
###begin p 67
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
* Receptor for advanced glycation end products (RAGE) knockout mice survive sepsis associated with cecal ligation and puncture better than do wild-type mice.
###end p 67
###begin p 68
###xml 73 79 <span type="species:ncbi:10090">murine</span>
* Administration of anti-RAGE monoclonal antibody improves survival in a murine model of polymicrobial sepsis, even when delayed up to 24 hours.
###end p 68
###begin p 69
###xml 69 75 <span type="species:ncbi:10090">murine</span>
* Administration of anti-RAGE monoclonal antibody is protective in a murine model of systemic listeriosis.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 232 235 232 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 302 308 <span type="species:ncbi:9913">bovine</span>
AGE = advanced glycation end products; CFU = colony-forming units; CLP = cecal ligation and puncture; HMGB-1 = high-mobility group box-1; Ig = immunoglobulin; IL = interleukin; IUCAC = Institutional Animal Care and Use Committee; LD50 = median lethal dose; mAb = monoclonal antibody; mBSA = methylated bovine serum albumin; MCP-1 = monocyte chemoattractant protein-1; ns = not significant; RAGE = receptor for advanced glycation end products; sRAGE = soluble receptor for advanced glycation end products; TNF = tumor necrosis factor; TSB = trypticase soy broth.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
ECL has received grant support from Wyeth Research. SMO has received grant support from Wyeth Research and clinical coordinating center support from Novartis International AG in Switzerland and Eisai Inc. (Woodcliff Lake, NJ, USA). DDP, JCK, X-YT, BMC, HP, KM, and YS are employees of Wyeth Research and own company stock. The other authors declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
ECL participated in study design and acquisition and interpretation of data and drafted the manuscript. SMO participated in study design, acquisition of data, and interpretation of data and helped draft the manuscript. DDP participated in conception of the study, analysis of RAGE knockouts and antibody, and revision of the manuscript. JCK participated in study design and interpretation of data. X-YT participated in the generation and characterization of RAGE antibody. BMC, HP, YS, and NAP participated in acquisition of data. KM participated in generation of RAGE knockouts. JEP participated in acquisition of data and performed statistical analysis. NK performed analysis of pathologic specimens. All authors read and approved the final manuscript.
###end p 75
###begin article-title 76
Therapeutic intervention and targets for sepsis
###end article-title 76
###begin article-title 77
A new paradigm for the treatment of sepsis: is it time to consider combination therapy?
###end article-title 77
###begin article-title 78
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
###end article-title 78
###begin article-title 79
###xml 100 106 <span type="species:ncbi:9913">bovine</span>
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
###end article-title 79
###begin article-title 80
The biology of the receptor for advanced glycation end products and its ligands
###end article-title 80
###begin article-title 81
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides
###end article-title 81
###begin article-title 82
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice
###end article-title 82
###begin article-title 83
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response
###end article-title 83
###begin article-title 84
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment
###end article-title 84
###begin article-title 85
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses
###end article-title 85
###begin article-title 86
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
###end article-title 86
###begin article-title 87
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system.
###end article-title 87
###begin article-title 88
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
###end article-title 88
###begin article-title 89
Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses
###end article-title 89
###begin article-title 90
Alarmin(g) news about danger
###end article-title 90
###begin article-title 91
Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein
###end article-title 91
###begin article-title 92
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
###end article-title 92
###begin article-title 93
###xml 51 56 <span type="species:ncbi:9606">human</span>
High mobility group 1 B-box mediates activation of human endothelium
###end article-title 93
###begin article-title 94
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response
###end article-title 94
###begin article-title 95
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
###end article-title 95
###begin article-title 96
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
###end article-title 96
###begin article-title 97
RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease
###end article-title 97
###begin article-title 98
Cellular resistance to infection
###end article-title 98
###begin article-title 99
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes</italic>
###xml 0 22 <span type="species:ncbi:1639">Listeria monocytogenes</span>
Listeria monocytogenes: clinical and experimental update
###end article-title 99

